KRAS Kickers

#KRAS 🎯cancer patient group for reliable Knowledge Research Advocacy & Survivorship. Survival of the strategic. #KickCancersKRAS - 🚫 #KRASholes

[KRAS Kickers @KRASKickers]

At @ASCO #GI26 we presented our KRAS KICKERS Trial Finder.

Personalized: KRAS G12D, CRC, US trials
Results (in 4 minutes): 20 trials

go to https://t.co/8waoJYVD9f
in beta - would love your feedback

abstract
https://t.co/NcRuZy6QYW

FYI:
G12V - 8 trials for CRC
G12R - 7 trials for CRC

[KRAS Kickers @KRASKickers]

as of July 30th, 170 sites for the EAP

[KRAS Kickers @KRASKickers]

The Expanded Access Program for Daraxonrasib now has 154 US locations (7/23/26)

new map:

[KRAS Kickers @KRASKickers]

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

phase 1/2 trial
International Trial, 55 locations
534 patients
opened November 2023

NCT06128551 TRIAL
https://t.co/TMbu0xssgO

[Anirban Maitra @Aiims1742]

New preprint from Maitra Lab alumni @FredrikThege @SonjaWoermann (Congratulations!)
Targeting AXL Overcomes Adaptive Resistance to KRAS Inhibition in KRAS-Driven #LungCancer and #PancreaticCancer
https://t.co/Y7uvEJBgBj
Next - KRASi + AXLi combination trials to sustain responses.

[Anirban Maitra @Aiims1742]

New study @KalluriLab dissecting the mechanism behind why CTLA-4 blockade is effective combined with KRASi:
Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in #PancreaticCancer
https://t.co/je00EWW65X

[KRAS Kickers @KRASKickers]

NCT07397338 - now in 9 US locations

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors

daraxonrasib (pan-RAS inhibitor)
elironrasib (KRAS G12C inhibitor)
zoldonrasib (KRAS G12D inhibitor

[KRAS Kickers @KRASKickers]

New Ph 1/2 trial
Study of RAS(ON) Inhibitors in Combination W/ Ivonescimab in Pts W/ Solid Tumors

Opened Jan 2026
Expansion to 5 US sites
370 pts

Arm A: daraxonrasib in comb w/ ivonescimab
Arm B: elironrasib in comb w/ ivonescimab
Arm C: zoldonrasib in comb w/ ivonescimab

NCT07397338
https://t.co/cTEOBgPvwN

Revolution Medicines presentations
https://t.co/aJgQzrrEA2

[Anirban Maitra @Aiims1742]

As Daraxonrasib is on the cusp of approval for #PancreaticCancer, @nyulangone onco-dermatologist Ian Tattersall discusses common side effects, including skin rash, & how to mitigate these.
The drug is currently available through the EAP at @Perlmutter_CC.
https://t.co/zTCzwLSraK

[KRAS Kickers @KRASKickers]

KRAS vaccine + bot/bal

"Phase 1b study evaluating the efficacy & immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined w/ Balstilimab & Botensilimab for unresectable or metastatic mismatch repair-proficient (MMR-p) colorectal cancer (mCRC) or unresectable or metastatic MMR-p pancreatic ductal adenocarcinoma (PDAC) pts w/ measurable disease following first-line chemotherapy"

NCT06411691 - enrolling at @hopkinskimmel
https://t.co/W5JeCmn04U

Opened Nov 2024, Ph 1, 54 pts

[Verastem Oncology @VerastemOncolog]

Today, we announced that the first patient has been dosed in TARGET-D 203, our Phase 2 registration-directed study evaluating VS-7375 for in patients with KRAS G12D-mutated metastatic colorectal cancer. ​
​
With this milestone, all three TARGET-D registration-directed Phase 2 clinical trials across pancreatic (TARGET-D 201), and non-small cell lung cancers (TARGET-D 202) are actively enrolling patients.​
​
Read more: https://t.co/6yLXDKQxDR

#ColorectalCancer #CRC #KRAS #CancerResearch #ClinicalTrials #RASPathway $VSTM

[AACR @AACR]

From RAS Inhibitors to RAS Degraders:
Terri D. Conneran, Andreas Mantoulidis, Kathryn Smith, Anita C. Bellail, and Ignacio Garrido-Laguna discussed this topic in an #AACRdrugdev26 plenary chaired by Rona Yaeger.
@RonaYaeger @GarridoLagunaMD"

[OncLive.com @OncLive]

Daraxonrasib is now under FDA review for pretreated metastatic pancreatic ductal adenocarcinoma.

Watch as @DrShubhamPant of @UTMDAnderson breaks down key findings from RASolute 302 that could help support FDA approval and the potential significance for daraxonrasib in pancreatic cancer management #pancsm #oncology

https://t.co/3LlCrohL3q

[NEJM @NEJM]

Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) https://t.co/y4G27hfORg

Editorial: Breaking the RAS Barrier in Pancreatic Cancer https://t.co/DbeFbZsu9r

#Oncology

[KRAS Kickers @KRASKickers]

The Expanded Access Program for Daraxonrasib now has 154 US locations (7/23/26)

new map:

[KRAS Kickers @KRASKickers]

Daraxonrasib EAP -
continued expansion to 125 sites (as of 7/11).
Was 73 sites as of 7/6/26

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

NCT07573215 - Map + Hawaii + Alaska
https://t.co/c0ULbX2QuM

@RevMedicines EAP access policy https://t.co/ygU2WOiMXb

[Anirban Maitra @Aiims1742]

The final session of #AACRDrugDev26 (@AACR D3) looks absolutely amazing.
@KRASKickers @GarridoLagunaMD

[OncLive.com @OncLive]

Daraxonrasib is officially under review by the @US_FDA for previously treated metastatic pancreatic cancer

Under the FDA Commissioner's National Priority Voucher pilot program, review of the NDA could be completed in 1 to 2 months #pancsm #oncology https://t.co/su0LDuqdFL

[Nicholas Hornstein @GIMedOnc]

This is the daraxonrasib news I’ve been refreshing the RevMed site for!

The NDA has been accepted for FDA review.

And before anyone says it: no, this is not “late.”

NDA packets are enormous. Clinical data, CMC, safety, labeling, subgroup analyses, QA, regulatory back-and-forth. It takes time to package a drug for FDA review, especially when the goal is not “nice phase 1 signal” but actual approval.

Now the timer starts. ⏱️

Why does this matter?
An oral RAS inhibitor with phase 3 PFS and OS benefit is a big deal. I think we've all said that enough by now.

Now the FDA gets to do what it has said it wants to do:
Get life-saving drugs into patients’ hands as quickly as possible (outside of an EAP program).

FDA clock officially started. ⏱️

https://t.co/mC9hFUnXur

@TheGutOncLab @OncoAlert @oncodaily @Onco_Nexus

[David S. Hong MD @DavidHongMD]

Ignition!

[KRAS Kickers @KRASKickers]

@keisan_15 @Aiims1742 @RevMedicines Thank you! It's almost too good to be true!

(Although US patients still will need NCCN recommendation to have insurance cover the meds. But I have a feeling those PDAC docs are quite motivated to research and discuss!)

[Revolution Medicines @RevMedicines]

The U.S. FDA accepted our New Drug Application for our oral RAS(ON) multi-selective inhibitor for previously treated metastatic pancreatic cancer.

Read more: https://t.co/8YyHJMyECv

[KRAS Kickers @KRASKickers]

Today's News:

Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

https://t.co/He2QUKzuqM

@RevMedicines
@DavidHongMD @kevansf
@GarridoLagunaMD @Sandra_Misale